Alnylam Pharmaceuticals Inc Stock

$260.51-0.51 (-0.2%)
Updated Jul 12, 2024
ALNY Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 1, 2024
Next Dividend

ALNY Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALNY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALNY is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ALNY's Earnings (EBIT) of -$197.22M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ALNY due diligence checks available for Premium users.

Be the first to know about important ALNY news, forecast changes, insider trades & much more!



ALNY price to earnings (PE)

For valuing profitable companies with steady earnings

ALNY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

ALNY's financial health

Profit margin

Net Income
Profit Margin
ALNY's Earnings (EBIT) of -$197.22M... subscribe to Premium to read more.
Interest Coverage Financials
ALNY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
ALNY's short-term assets ($2.99B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALNY's long-term liabilities ($3.10B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALNY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

ALNY's operating cash flow ($189.12M)... subscribe to Premium to read more.
Debt Coverage Financials

ALNY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Alnylam Pharmaceuticals Stock FAQ

What is Alnylam Pharmaceuticals's quote symbol?

(NASDAQ: ALNY) Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol ALNY. Alnylam Pharmaceuticals stock quotes can also be displayed as NASDAQ: ALNY.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

What is the 52 week high and low for Alnylam Pharmaceuticals (NASDAQ: ALNY)?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's 52-week high was $263.73, and its 52-week low was $141.98. It is currently -1.22% from its 52-week high and 83.49% from its 52-week low.

How much is Alnylam Pharmaceuticals stock worth today?

(NASDAQ: ALNY) Alnylam Pharmaceuticals currently has 126,491,778 outstanding shares. With Alnylam Pharmaceuticals stock trading at $260.51 per share, the total value of Alnylam Pharmaceuticals stock (market capitalization) is $32.95B.

Alnylam Pharmaceuticals stock was originally listed at a price of $7.00 in Jun 1, 2004. If you had invested in Alnylam Pharmaceuticals stock at $7.00, your return over the last 20 years would have been 3,621.57%, for an annualized return of 19.82% (not including any dividends or dividend reinvestments).

How much is Alnylam Pharmaceuticals's stock price per share?

(NASDAQ: ALNY) Alnylam Pharmaceuticals stock price per share is $260.51 today (as of Jul 12, 2024).

What is Alnylam Pharmaceuticals's Market Cap?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's market cap is $32.95B, as of Jul 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alnylam Pharmaceuticals's market cap is calculated by multiplying ALNY's current stock price of $260.51 by ALNY's total outstanding shares of 126,491,778.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.